|
⚲
|
| Keyboard |
| Cormorant Asset Management LP
✚
|
|
|---|---|
| CRD # | 167820 |
| SEC # | 801-79513 |
| CIK # | 0001583977 |
| AUM | 3,838.6 M (2026-05-27) |
| Employees | 12 (25% Investors, 0% Brokers) |
| Phone | 857-702-0370 |
| Address | 200 Clarendon Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 0.3 | ||
| Helix Acquisition Corp II | 0.2 | ||
| Psivida Corp | 0.1 | ||
| Edgewise Therapeutics Inc | 0.1 | ||
| Erasca Inc | 0.1 | ||
| Rapport Therapeutics Inc | 0.1 | ||
| Alumis Inc | 0.1 | ||
| Abivax Sa | 0.1 | ||
| Helix Acquisition Corp | 0.1 | ||
| Magenta Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Cormorant Private Healthcare Fund VI LP | [2026-02-11] | 75.2 M | 102.9 M |
| Offered $400,000,000 · Filed 2025-11-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining $324,800,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund V LP | [2023-11-13] | 318.0 M | 491.7 M |
| Offered $318,000,000 · Filed 2024-08-08 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Minimum $5,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund IV LP | [2021-11-15] | 252.7 M | 426.3 M |
| Offered $400,000,000 · Filed 2021-08-03 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $147,314,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund III LP | [2020-11-27] | 206.3 M | 429.5 M |
| Offered $419,913,000 · Filed 2021-06-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $213,650,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund II LP | [2018-11-26] | 105.5 M | 125.2 M |
| Offered $350,000,000 · Filed 2018-08-17 (D) · Exemption 506(b), 3(c)(7) · Remaining $244,450,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Cormorant Private Healthcare Fund I LP | [2016-03-30] | 29.0 M | 49.8 M |
| Offered $250,000,000 · Filed 2016-01-15 (D) · Exemption 506(b), 3(c)(7) · Minimum $5,000,000 · Remaining $221,040,010 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Cormorant Global Healthcare Master Fund LP | [2013-06-14] | 589.2 M | 2,204.4 M |
| Filed 2026-03-03 (D/A) · Exemption 506(b) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 15 | 3.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.0 |
| Total | 16 | 3.8 |
| By Discretionary | ||
| Discretionary | 16 | 3.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 16 | 3.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.8 | |
| United States Persons | 3.1 | |
| Total | 16 | 3.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Kevin Phillip | Director | 193 | 39 | |
| Paras Malde | Director | 77 | 26 | |
| Dms Fund Governance I Ltd | Director | 10 | 4 | |
| Jay Scollins | Executive Officer | 17 | 3 | |
| Dms Fund Governance II Ltd | Director | 6 | 3 | |
| Bihua Chen | Executive Officer | 48 | 2 | |
| Cormorant Asset Management LP | Executive Officer, Promoter | 12 | 2 | |
| Caleb Tripp | Executive Officer | 8 | 2 | |
| Cormorant Asset Management LLC | Executive Officer, Promoter | 4 | 2 | |
| Cormorant Private Healthcare GP II LLC | Executive Officer | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001583977] | |
| 3 | [0001583977] | |
| 4 | [0001583977] | |
| SC 13D | [0001583977] | |
| SC 13G | [0001583977] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
SAV Acquisition Corp CRBP
Common Stock
|
2025-12-11 | Sell | 30,029 | $11.46 | 344,132 |
|
EyePoint Inc EYPT
Common Stock
|
2025-12-04 | Sell | 60,000 | $15.70 | 942,000 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-30 | Sell | 5,827 | $6.96 | 40,556 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 2,800,000 | $6.61 | 18,508,000 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 3,390,943 | $7.58 | 25,703,348 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 232,460 | $8.40 | 1,952,664 |
|
MoonLake Immunotherapeutics MLTX
Class A Ordinary Shares
|
2025-09-29 | Sell | 70,748 | $9.38 | 663,616 |
|
Biomea Fusion Inc BMEA
Stock Option (Right to Buy) · derivative
|
2025-06-11 | Grant | 91,970 | $0.00 | |
|
OnKure Therapeutics Inc OKUR
Class A Common Stock
|
2025-05-15 | Sell | 1,813,439 | $1.85 | 3,354,862 |
|
OnKure Therapeutics Inc OKUR
Class A Common Stock
|
2025-05-12 | Sell | 24,300 | $1.99 | 48,357 |
|
Aardvark Therapeutics Inc AARD
Series C Convertible Preferred Stock · derivative
|
2025-02-14 | Conversion | 6,780,810 | ||
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Buy | 187,500 | $16.00 | 3,000,000 |
|
Aardvark Therapeutics Inc AARD
Common Stock
|
2025-02-14 | Conversion | 800,189 | ||
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-11-04 | Buy | 184,331 | $21.70 | 3,999,983 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 7,150 | $24.03 | 171,814 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 39,743 | $23.22 | 922,832 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-16 | Buy | 3,107 | $25.22 | 78,359 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 63,173 | $5.92 | 373,984 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 33,343 | $6.42 | 214,062 |
|
Bright Minds Biosciences Inc DRUG
Common Shares
|
2024-10-15 | Buy | 8,900 | $7.31 | 65,059 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hudson Structured Capital Management Ltd
✚
|
CT | 4,028.4 M |
|
Glade Brook Capital Partners LLC
✚
|
CT | 3,955.0 M |
|
Avenue Europe International Management LP
✚
|
NY | 3,912.4 M |
|
Cyrus Capital Partners LP
✚
|
NY | 3,866.5 M |
|
Tree Line Capital Partners LLC
✚
|
CA | 3,847.7 M |
|
Vector Capital Management LP
✚
|
CA | 3,751.0 M |
|
Anchorage Capital Group LLC
✚
|
NY | 3,707.6 M |
|
Resource Capital Investment Corporation
✚
|
CA | 3,706.7 M |
|
Boussard & Gavaudan Investment Management LLP
✚
|
3,679.1 M | |
|
Soleus Capital Management LP
✚
|
CT | 3,663.3 M |